SCHEMBL734030

SCHEMBL734030

COC(=O)CCC(C#N)(CCC(=O)OC)c1ccccc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNN4 O15554 1/20 0.42
ALDH1A1 P00352 4/20 0.42
TSHR P16473 3/20 0.42
HPGD P15428 1/20 0.42
LMNA P02545 3/20 0.41
KDM4E B2RXH2 1/20 0.41
AKT1 P31749 1/20 0.40
KCNA3 P22001 1/20 0.39
MAPT P10636 2/20 0.39
KMT2A Q03164 2/20 0.39
HTT P42858 1/20 0.39
HSD17B10 Q99714 1/20 0.39
CA12 O43570 1/20 0.38
CA7 P43166 1/20 0.38
CA9 Q16790 1/20 0.38
CA14 Q9ULX7 1/20 0.38
ESRRB O95718 1/20 0.38
POLB P06746 1/20 0.38
EBP Q15125 1/20 0.38
SIGMAR1 Q99720 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19145997 0.93 ALDH1A1 (0.42) KCNN4ALDH1A1TSHRHPGDLMNA
SCHEMBL3932718 0.91 ALDH1A1 (0.41) KCNN4ALDH1A1TSHRHPGDLMNA
SCHEMBL14996084 0.87 KCNA3 (0.40) KCNN4ALDH1A1TSHRHPGDLMNA
SCHEMBL11817907 0.85 MAPT (0.40) ALDH1A1LMNAKDM4EMAPTKMT2A
SCHEMBL11821360 0.85 CA12 (0.41) ALDH1A1TSHRHPGDLMNAKDM4E
SCHEMBL11845684 0.85 SMN1; SMN2 (0.50) ALDH1A1KCNA3KMT2APOLBEBP
SCHEMBL11818519 0.85 ALDH1A1 (0.47) ALDH1A1LMNAMAPTKMT2AHTT
SCHEMBL20698826 0.84 CCR1 (0.43) KCNN4ALDH1A1TSHRHPGDLMNA
SCHEMBL4431139 0.84 CNR1 (0.41) ALDH1A1TSHRHPGDLMNAMAPT
SCHEMBL7749213 0.83 TBXAS1 (0.41) ALDH1A1LMNAKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2041142-B1 SPIROCYCLIC AZAINDOLE DERIVATIVES GRUENENTHAL GMBH (DE) 2013-10-09 EP disclosed
US-8399503-B2 Spirocyclic azaindole derivatives GRUENENTHAL GMBH (DE) 2013-03-19 US disclosed
EP-2044016-B1 4-HETEROARYL-SUBSTITUTED 1-AMINOCYCLOHEXANE-1-AND CYCLOHEXENE-1-DERIVATIVES HAVING EFFECTS ON THE OPIOD RECEPTOR SYSTEM GRUENENTHAL GMBH (DE) 2012-12-05 EP disclosed
US-8138187-B2 Substituted heteroaryl derivatives GRUENENTHAL GMBH (DE) 2012-03-20 US disclosed
US-20100009986-A1 SUBSTITUTED HETEROARYL DERIVATIVES GRUNENTHAL GMBH (DE) 2010-01-14 US disclosed
US-20090156593-A1 Spirocyclic Azaindole Derivatives GRUNENTHAL GMBH (DE) 2009-06-18 US disclosed
EP-2044016-A2 4-HETEROARYL-SUBSTITUTED 1-AMINOCYCLOHEXANE-1-AND CYCLOHEXENE-1-DERIVATIVES HAVING EFFECTS ON THE OPIOD RECEPTOR SYSTEM Grünenthal GmbH (DE) 2009-04-08 EP disclosed
EP-2041142-A1 SPIROCYCLIC AZAINDOLE DERIVATIVES Grünenthal GmbH (DE) 2009-04-01 EP disclosed
WO-2008009416-A1 SPIROCYCLIC AZAINDOLE DERIVATIVES Grünenthal GmbH (DE) 2008-01-24 WO disclosed
WO-2008009415-A2 4-HETEROARYL-SUBSTITUTED 1-AMINOCYCLOHEXANE-1- AND CYCLOHEXENE-1-DERIVATIVES HAVING EFFECTS ON THE OPIOD RECEPTOR SYSTEM Grünenthal GmbH (DE) 2008-01-24 WO disclosed
US-3979444-A CENTRAL NERVOUS SYSTEM DEPRESSANTS, HYPOTENSIVES THE UPJOHN COMPANY (US) 1976-09-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156593-A1 Spirocyclic Azaindole Derivatives AZI2, TPMT, AADAC KCNN4 3046/4885ALDH1A1 709/4885TSHR 2673/4885
US-20100009986-A1 SUBSTITUTED HETEROARYL DERIVATIVES CYP3A43, HMGCR, ABCG2 KCNN4 4310/4885ALDH1A1 3171/4885TSHR 3876/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.